Shenmai injection is commonly used for treatment of shock, coronary heart disease, viral myocarditis, chronic pulmonary heart disease and neutropenia. After going on market drugs can have effectiveness and safety that differ from our expectation. Thus, post-marketing evaluation is both necessary and essential. The research will summarize series of studies of Shenmai injection conducted by our team (bibliometric analysis, systems analysis, electronic medical data analysis and safety data analysis of spontaneous reporting system), to provide scientific basis for proper use.